Safety and efficacy of combined dual antiplatelet therapy and factor VIII prophylaxis in patients with haemophilia A after acute coronary syndrome

被引:1
作者
Agosti, Pasquale [1 ,2 ]
Siboni, Simona Maria [2 ]
Ciavarella, Alessandro [1 ,2 ]
Arcudi, Sara [2 ]
Boggio, Federico [1 ]
Gualtierotti, Roberta [1 ,2 ]
Peyvandi, Flora [1 ,2 ]
机构
[1] Univ Milan, Dept Pathophysiol & Transplantat, Via Pace 9, I-20122 Milan, Italy
[2] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Angelo Bianchi Bonomi Haemophilia & Thrombosis Ctr, Via Pace 9, I-20122 Milan, Italy
关键词
acute coronary syndrome; antiplatelet drugs; factor VIII; Haemophilia A; preventive therapy; ELDERLY-PATIENTS; MORTALITY; DISEASE; RISK; MANAGEMENT; PEOPLE; DEATH;
D O I
10.1111/hae.14963
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionThe increased life expectancy of patients with haemophilia A (HA) has led to a growing prevalence of cardiovascular risk factors and events. There is still scarce evidence on the safety and appropriate duration of dual antiplatelet therapy (DAPT) after acute coronary syndrome (ACS) in HA patients.AimWe describe our experience on the clinical management of Italian HA patients after ACS.MethodsNine patients with congenital HA treated with DAPT after a revascularization procedure performed for ACS have been enrolled and followed at the Angelo Bianchi Bonomi Haemophilia and Thrombosis Center in Milan between 2005 and September 2022. The safety and efficacy of DAPT with or without FVIII prophylaxis were assessed.ResultsTen ACS events occurred in the nine HA patients (four mild and five severe). All events were treated with percutaneous transluminal coronary angioplasty with deployment of 1 to 3 drug-eluting stents followed by DAPT for 1-12 months. All patients except one were treated with FVIII prophylaxis during DAPT aimed at achieving FVIII trough levels >= 20-30 IU/dL. DAPT was effective in all cases in preventing early ACS recurrence, with only a late recurrence. We observed two clinically relevant non-major bleeds (one in a patient without FVIII prophylaxis) and three minor bleeds. No venous thrombosis occurred.ConclusionThe long-term secondary antithrombotic prevention consisting of DAPT and FVIII prophylaxis achieving a trough level of 20-30 IU/dL can be effective and safe in HA patients.
引用
收藏
页码:336 / 344
页数:9
相关论文
共 40 条
[1]   Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials) [J].
Attar, Rubina ;
Wu, Angie ;
Wojdyla, Daniel ;
Jensen, Svend Eggert ;
Andell, Pontus ;
Mahaffey, Kenneth W. ;
Roe, Matthew T. ;
James, Stefan K. ;
Wallentin, Lars ;
Vemulapalli, Sreekanth ;
Alexander, John H. ;
Lopes, Renato D. ;
Ohman, E. Magnus ;
Hernandez, Adrian F. ;
Patel, Manesh R. ;
Jones, W. Schuyler .
AMERICAN JOURNAL OF CARDIOLOGY, 2022, 178 :11-17
[2]   The Hypertension of Hemophilia Is Not Explained by the Usual Cardiovascular Risk Factors: Results of a Cohort Study [J].
Barnes, Richard F. W. ;
Cramer, Thomas J. ;
Sait, Afrah S. ;
Kruse-Jarres, Rebecca ;
Quon, Doris V. K. ;
von Drygalski, Annette .
INTERNATIONAL JOURNAL OF HYPERTENSION, 2016, 2016
[3]   Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial [J].
Becker, Richard C. ;
Bassand, Jean Pierre ;
Budaj, Andrzej ;
Wojdyla, Daniel M. ;
James, Stefan K. ;
Cornel, Jan H. ;
French, John ;
Held, Claes ;
Horrow, Jay ;
Husted, Steen ;
Lopez-Sendon, Jose ;
Lassila, Riitta ;
Mahaffey, Kenneth W. ;
Storey, Robert F. ;
Harrington, Robert A. ;
Wallentin, Lars .
EUROPEAN HEART JOURNAL, 2011, 32 (23) :2933-2944
[4]   Incidence and Cost of Major Adverse Cardiovascular Events and Major Adverse Limb Events in Patients With Chronic Coronary Artery Disease or Peripheral Artery Disease [J].
Berger, Ariel ;
Simpson, Alex ;
Bhagnani, Tarun ;
Leeper, Nicholas J. ;
Murphy, Brian ;
Nordstrom, Beth ;
Ting, Windsor ;
Zhao, Qi ;
Berger, Jeffrey S. .
AMERICAN JOURNAL OF CARDIOLOGY, 2019, 123 (12) :1893-1899
[5]   Factor VIII deficiency does not protect against atherosclerosis [J].
Biere-Rafi, S. ;
Tuinenburg, A. ;
Haak, B. W. ;
Peters, M. ;
Huijgen, R. ;
de Groot, E. ;
Verhamme, P. ;
Peerlinck, K. ;
Visseren, F. L. J. ;
Kruip, M. J. H. A. ;
Laros-van Gorkom, B. A. P. ;
Gerdes, V. E. A. ;
Buller, H. R. ;
Schutgens, R. E. G. ;
Kamphuisen, P. W. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (01) :30-37
[6]  
Biere-Rafi S, 2010, NETH J MED, V68, P207
[7]   Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens [J].
Carvalho, Joana Rita ;
Velosa, Jose ;
Serejo, Fatima .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2018, 53 (07) :857-863
[8]   Management of cardiovascular disease in haemophilia [J].
Cayla, Guillaume ;
Morange, Pierre-Emmanuel ;
Chambost, Herve ;
Schved, Jean-Francois .
THROMBOSIS RESEARCH, 2013, 132 (01) :8-14
[9]   Challenges of antithrombotic therapy in the management of cardiovascular disease in patients with inherited bleeding disorders: A single-centre experience [J].
Cohen, Oliver C. ;
Bertelli, Michele ;
Manmathan, Gavin ;
Little, Callum ;
Riddell, Anne ;
Pollard, Debra ;
Aradom, Elsa ;
Mussara, Molly ;
Harrington, Chris ;
Kanagasabapathy, Pamela ;
De Silva, Ravi ;
Martin, Bruce ;
Peralta, Rita ;
Gomez, Keith ;
Yee, Thynn ;
Chowdary, Pratima ;
Rakhit, Roby D. .
HAEMOPHILIA, 2021, 27 (03) :425-433
[10]  
Collet JP, 2021, REV ESP CARDIOL, V74, DOI [10.1093/eurheartj/ehaa575, 10.1016/j.rec.2021.05.002]